Acknowledgments
IRD, Acoziborole
SLEEPING SICKNESS
This study was funded through the DNDi and was supported by grants from the Bill & Melinda Gates Foundation (INV002384 and INV-008203); UK Aid; the Federal Ministry of Education and Research (BMBF) through Kreditanstalt für Wiederaufbau (known as KfW), Germany; the Swiss Agency for Development and Cooperation (SDC); Médecins Sans Frontières; the Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; the Norwegian Agency for Development Cooperation (Norad), Norwegian Ministry of Foreign Affairs, as part of Norway's in-kind contribution to the second European & Developing Countries Clinical Trials Partnership programme (EDCTP2); the Stavros Niarchos Foundation; the Spanish Agency for International Development Cooperation (AECID), Spain; the Banco Bilbao Vizcaya Argentaria (known as BBVA) Foundation (through the Frontiers of Knowledge Award in Development Cooperation). The opinions expressed in this Article do not necessarily reflect the position or policies of any of the funding bodies. Acoziborole is the result of a collaboration between the DNDi, Anacor Pharmaceuticals, and SCYNEXIS. We thank the patients, nurses, laboratory technicians, and other staff members who participated in this study; the staff from the Kinshasa and Geneva offices for high-quality logistical and administrative support; and the representatives of sponsors who were involved in data gathering and analyses. We extend our thanks to the Institut National de Recherche Biomédicale for their support of technical laboratory standard operational procedures, writing and training activities, and direct supervision of laboratories at the sites (Dieudonné Mumba Ngoyi [head], Patient Pyana Pati [coordinator of quality assurance], and Josès Dinanga and Dieudonné Tshimanga [supervisors]). We are grateful to Christian Burri, Elisabeth Reus, Marcel Benanduenga, Clovis Mwamba, and Yves Lula of the Swiss Tropical and Public Health Institute for study coordination and monitoring in the Democratic Republic of the Congo; Marguerite Crato Cisse and Maïmouna Mbaye of Santé Plus for monitoring of the Guinean study site; Mohamed Sam Bangoura of the National Sleeping Sickness Control Programme (PNLTHA) for administrative support in Guinea; Oumou Camara of the French National Research Institute for Sustainable Development (IRD) for laboratory supervision in Guinea; and United BioSource for pharmacovigilance support. We thank Frederic Mistretta, Jean-Sylvain Larguier, Aurore Magny, Flavien Roux, Fabien Sorin, Karine Posada, and Michèle-Johanne Ribaud for data management and statistical analysis; Nathalie Radet, Nadine Vallomi, and Chantal Raffy of Theradis Pharma for biological sample management; Pere Simarro for invaluable advice; Bruno Bucheton for support in Guinea; Pascal Voiriot, Catherine Da Silva, and Fanny Schoose of Banook group for support in electrocardiograms (ECG) handling and analysis; Mathieu Felices for support in ECG analysis and interpretation; Virginie Gualano and Sarah Lezzar for support in pharmacokinetic analysis and interpretation of PhinC Development; Valerie Wauthier and Romuald Sable of Société Générale de Surveillance (known as SGS) for their participation in dry blood spot sampling analysis; Scinopsis for providing medical writing services funded by the DNDi; Jean-François Louvion for data-management expertise; and Graham Smith for translation services. Special thanks to Louise Burrows of the DNDi for carefully editing the manuscript and to Nathalie Salichon of the DNDi for support during the study.